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ABSTRACT Oil palm (Elaeis guineensis) leaf extract (OPLE) possesses good ex vivo vasodilation and antioxidant prop-
erties. This study evaluated the catechin-rich OPLE antioxidant, antihypertensive, and cardiovascular effects in normal and
nitric oxide (NO)–deficient hypertensive rats. OPLE was administered orally (500 mg=kg of body weight=day) to normo-
tensive Wistar rats and Nx-nitro-l-arginine methyl ester (l-NAME)-induced NO-deficient hypertensive rats. OPLE signifi-
cantly (P < .05) attenuated blood pressure increases, increased serum NO, reduced lipid peroxidation, and showed antioxidant
effects in NO-deficient hypertensive rats. OPLE decreased the coronary arteriole wall-to-lumen ratio to near normal values
under NO deficiency. Although OPLE showed good antihypertensive and antioxidant effects under NO deficiency, it was not
hypotensive to normal rats and produced no chronic cardiovascular toxicity in any of the rats throughout the 12-week study.
This is the first report on the in vivo antihypertensive properties of green tea catechins extracted from an alternative source,
namely, oil palm leaf, for use as a medicinal food for hypertension and cardiovascular ailments.
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INTRODUCTION
Methanolic oil palm (Elaeis guineensis) leaf extract(OPLE) is rich in polyphenols.1 The health benefits
of green tea catechins for the prevention of cancer,2,3 in-
flammation,4 arthritis,5 bacterial infections,6 angiogenesis,7
oxidation,8 viral infections,9 neurodegeneration,10 and hy-
percholesterolemia11 have been well documented.12 How-
ever, the scarce reports on the antihypertensive effects of
catechins in vivo warrant further investigation and confir-
mation. The polyphenol-rich OPLE showed vasodilative
properties on noradrenaline-preconstricted rat aorta and
mesenteric arterial bed, mainly via endothelium-dependent
mechanisms.13 The OPLE also effectively inhibited low-
density lipoprotein oxidation better than other edible
plant extracts.14
The demand for cost-effective, safe, and effective me-
dicinal foods for treating hypertension and cardiovascular
disease is increasing. Palm leaves are underutilized by-
products of the palm oil industry that can be a potential
source of beneficial compounds. The discovery of the
ex vivo vasodilation and antioxidant properties of OPLE
initiated this investigation on the in vivo antihypertensive
and antioxidative effects of OPLE in nitric oxide (NO)–
deficient hypertensive rats. However, sometimes ex vivo
effects are not reproduced in whole animals. The total OPLE
was used because pure compounds may not exert similar
vasorelaxant and antioxidative effect like the whole extract.
MATERIALS AND METHODS
Materials
All chemicals were of analytical grade and were from
Sigma-Aldrich (Kuala Lumpur, Malaysia). Captopril, Nx-
nitro-l-arginine methyl ester (l-NAME), thiobarbituric
acid, and 1,1,3,3-tetraethoxypropane were from Sigma-
Aldrich. Ketamine and xylazine were from the Veterinary
Hospital, Faculty of Veterinary Medicine, Universiti Putra
Malaysia, Serdang, Selangor, Malaysia. Pyrogallol, reduced
glutathione, and dithio-bis(2-nitrobenzoic acid) were from
Merck (Kuala Lumpur, Malaysia).
Oil palm (E. guineensis) leaves from the Universiti Putra
Malaysia plantation were coarsely chopped and dried in a
40C oven for 24 hours. The dried material was milled and
extracted with methanol using a 1:10 (wt=vol) solvent ratio,
under continuous agitation (turbo extractor) at room tem-
perature for 2 hours. After filtration, the solvent was com-
pletely removed in a rotary evaporator under vacuum at
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40C. The extract was stored in glass jars flushed with ni-
trogen at -20C.
Identification of compounds in the extract
The OPLE (80 mg) was hydrolyzed in 6 M HCl at 95C
and refluxed for 2 hours in a steam bath. The sample was
cooled and filtered through a nylon membrane filter (pore
size, 0.4lm) (Whatman, Maidstone, United Kingdom) be-
fore being injected into a reverse-phase high-performance
liquid chromatograph on a Symmetry C18 column
(150 · 3.9 mm; particle size, 5 lm) (Waters Corp., Milford,
MA, USA), using acidified water (trifluoroacetic acid at pH
2.5) and methanol as the mobile phase, on a gradient run,
with an ultraviolet detector at 280 nm. Pure standards [(+)-
catechin, (-)-epicatechin, epigallocatechin (EGC), EGC
gallate (EGCG), epicatechin gallate (ECG), quercetin,
myricetin, kaempferol, and rutin] were used as internal and
external standards to identify the compounds.
The high-performance liquid chromatography result
showed that the main phenolic compounds in OPLE were
the green tea catechins, namely, EGC (0.08%), catechin
(0.30%), epicatechin (0.01%), EGCG (0.28%), and ECG
(0.05%).
Animals
Male Wistar Kyoto (WKY) rats, 16 weeks old, were di-
vided into six groups of eight rats per group: (1) normal
control rats; (2) normal rats given OPLE; (3) normal rats
given captopril; (4) l-NAME-induced NO-deficient rats
given vehicle; (5) l-NAME-induced NO-deficient rats given
OPLE; and (6) l-NAME-induced NO-deficient rats given
captopril. The rats were maintained on distilled water and a
standard rat chow (Gold Coin Sdn. Bhd., Klang, Malaysia)
for 14 days and kept in a well-ventilated room with a 12-
hour dark=light cycle before the study. Measures were taken
to minimize pain or discomfort, and experiments were car-
ried out in accordance with the animal ethics approval of the
Universiti Putra Malaysia.
Soy oil was used as the vehicle for dissolving and dis-
pensing OPLE (500 mg of OPLE=kg=day by oral gavage) at
a concentration of 100 mg=mL. The dose of 500 mg=kg was
used in accordance with previous studies on green tea cat-
echins15 and shown to be nontoxic to rats.16 Water-soluble
l-NAME (60 mg=L) was administered in the drinking
water. Water-soluble captopril (100 mg=kg=day) was co-
administered with l-NAME in the drinking water as the
positive standard drug. The vehicle was administered in all
rats at similar amounts and with a similar method to rats
receiving OPLE.
Blood samples (2 mL) from nonfasting rats were obtained
in the morning via cardiac puncture with the animal under
ketamine=xylazine (ketamine, 50 mg=kg; xylazine, 5 mg=kg)
combination anesthesia, at weeks 0, 6, 9, and 12. Hepar-
inized tubes (for plasma) and tubes with no additive (for
serum) were used. The heparinized blood was kept on ice,
and the plasma was recovered by centrifugation at 3,000 g at
4C for 15 minutes. Erythrocytes were washed three times
with an equal volume of saline and centrifuged at 3,000 g for
15 minutes in between washings. Aliquots of the washed
erythrocytes and plasma were frozen at -80C until ana-
lyzed. Blood collected with no-additive tubes was incubated
at 37C and left to fully clot for 90 minutes, after which it
was centrifuged at 3,000 g for 15 minutes. An aliquot of the
resultant serum was collected and frozen at -80C until
assayed.
Blood pressure
Indirect systolic blood pressure (BP) was measured in rats
within 10 minutes of immobilization, under mild intra-
muscular ketamine=xylazine anesthesia (a dose similar to
those used during blood sampling) using noninvasive tail
cuff BP plethysmography (Powerlab system for data han-
dling, ADInstruments, Sydney, Australia). BP was taken
before noon, and for each rat values were averaged from five
readings. A preliminary study confirmed that BP values
measured within 10 minutes of immobilization in ketami-
ne=xylazine-anesthetized rats were similar to that of con-
scious rats.17 Diastolic BP was not measured because the
noninvasive BP is limited to only measuring systolic BP.
Antioxidant activities
Serum NO was measured using a standard method
(modified Griess reagent for NO2=NO3 assay) and measur-
ing absorbance at 540 nm with a microplate reader (Thermo
Labsystems, Beverly, MA, USA) after 15 minutes. Sodium
nitrite (5–100 ppm) solutions were used for calibrating the
nitrite concentration.
The antioxidant enzyme activities in tissues were deter-
mined. For superoxide dismutase (SOD) activities, the ab-
sorbances of 500lL of hemolysate (1 part packed
erythrocytes to 3 parts ice-cold deionized water) and the
average of four preparations of blank control were used to
calculate the enzyme unit, which is the amount that inhibits
50% pyrogallol reaction.18
For catalase activities, 1 part packed erythrocytes to 4
parts ice-cold deionized water were mixed and then diluted
500 times with 50 mM pH 7.0 phosphate buffer. Two mil-
liliters of this was added to 1 mL of 30 mM hydrogen per-
oxide (H2O2), and the decrease in absorbance was followed
for 30 seconds.19 The H2O2 enzymatic decomposition fol-
lows a first-order reaction, and the rate constant (k) is a
direct measure of the catalase concentration.
For glutathione peroxidase (GSH-Px) activities, aliquots
of 400lL of hemolysate consisting of 1 part packed eryth-
rocytes mixed with 3 parts ice-cold deionized water were
used.20 One unit of enzyme activity was the decrease in the
log reduced glutathione concentration of 0.001=minute after
subtracting the decrease in log reduced glutathione con-
centration per minute for the nonenzymatic reaction.
Plasma malondialdehyde (MDA) was determined ac-
cording to standard proceedures,21 where plasma (300 lL)
was mixed with 42 mM H2SO4 (2.4 mL) and 10% aque-
ous sodium tungstate (300 lL) and vortex-mixed. After
10 minutes, the mixture was centrifuged at 3,000 g for
776 JAFFRI ET AL.
10 minutes. The pellet was resuspended in 450lL of dis-
tilled water and then vortex-mixed until homogeneous. Fifty
microliters of 7 mM tert-butylhydroxytoluene (in 50% eth-
anol solution), 3.0 mL of 0.05 M HCl, and 1.0 mL of 1%
aqueous thiobarbituric acid solution were added, mixed
thoroughly, heated immediately for 60 minutes at 95C, and
cooled with running water. n-Butanol (4 mL) was then ad-
ded and vortex-mixed for 60 seconds, after which the mix-
ture was centrifuged for 10 minutes at 3,000 g. The
absorbance of the organic layer was read at 532 nm against
pure n-butanol,21 using a Secoman (Anthelie, Domont,
France) Advance UV-visible spectrophotometer.
Histology study
Medial transverse sections of the hearts were fixed in 10%
neutral buffered formalin for histology studies. The re-
maining heart was immediately frozen at -80C until an-
alyzed. For the antioxidant enzyme and MDA analysis, the
frozen tissue was thawed overnight at 4–8C and minced
with surgical scissors before being homogenized in ice-cold
0.15 M KCl (4 mL for every 1 g of tissue) using a Silverson
(Chesham, United Kingdom) tabletop homogenizer set
(model L4RT). The homogenate was freed from cellular de-
bris and nuclei by centrifugation at 5,000 g at 4C for 20
minutes. The resultant supernatant was used for the bio-
chemical assays. Homogenate protein content was determined
and calibrated with bovine serum albumin.22 Organ somatic
index was measured as (organ mass=body mass)· 100.
Five-micrometer-thick tissue sections were depar-
affinized and processed routinely for hematoxylin and eosin
staining. Approximately 10 randomly selected fields of each
heart section were observed with a light microscope at · 100
magnification. The occurrence of myocardial fibrosis was
examined in each heart section, and the percentage was
estimated for every field. Myocardium and coronary arte-
riole wall thicknesses and lumen diameter were measured
with a ruler placed on the images captured at · 400 mag-
nification on a flat computer monitor. Five randomly se-
lected images of the myocardium and a minimum of two
images of the coronary arterioles from each heart section
were used for myocardial thickness and arterial measure-
ments, respectively. The myocardial fibers thicknesses (in
mm) were measured from the computer screen, solely for
comparison purposes. Wall-to-lumen ratios were calculated
as (wall thickness=lumen diameter) · 100. All images were
captured using a PixeLINK version 1.3 megapixel camera
(PixeLINK, Ottawa, Canada) mounted on a Leica DME
light microscope (Leica Microsystems, Buffalo Grove, IL,
USA).
All statistical analyses were performed using Minitab
(State College, PA, USA) version 13 statistical software,
and data were expressed as mean –SEM values. Significant
differences (P < .05) between groups were analyzed using a
one-way analysis of variance, followed by Tukey’s pairwise
comparison post hoc test.
RESULTS
The OPLE catechins were tested on normal and hyper-
tensive WKY rats. The average fluid intake per rat per day
was significantly higher compared with baseline in the
captopril and l-NAME groups (Table 1). The hypertensive
rats (l-NAME) showed significantly (P< .05) lower weight
gains by about 30% compared with normal rats (Table 2).
Captopril treatment of normal or hypertensive rats reduced
this weight gain further. The cardiosomatic index in l-NAME
and l-NAME+OPLE rats indicated about 20% hypertrophy
(Table 2) compared with the normotensive control rats.
Captopril prevented hypertrophy in l-NAME rats.
l-NAME gradually increased the WKY rats’ BP from
100–110 mm Hg to 140.00– 4.18 mm Hg within 1 week and
to about 175 mm Hg from week 2 onward. Co-administra-
tion of l-NAME with OPLE or captopril significantly at-
tenuated this BP increase to normal values (Fig. 1)
throughout the experimental duration. OPLE and captopril
caused no hypotensive or other apparent toxic effects in
normotensive rats. The BP in all normotensive rats was
Table 1. Effects of Chronic Treatments on Fluid and Food Intake of Rats
Average water intake (mL=rat=day) Average food intake (g=rat=day)
Group Week 0 Weeks 1–6 Weeks 7–12 Week 0 Weeks 1–6 Weeks 7–12
WKY
Control 35 – 2 33– 2 36 – 2 14 – 1 13 – 2 16– 5
+OPLE 38 – 2 35– 3 38 – 2 14 – 2 14 – 1 16– 2
+captopril 38 – 2 53– 2*a 56 – 2*a 15 – 1 15 – 2 17– 5
+l-NAME 35 – 4 40– 3 41 – 3*a 14 – 1 13 – 2 16– 5
+l-NAME+OPLE 38 – 3 49– 2*a 45 – 3*a 14 – 2 14 – 1 16– 2
+l-NAME+ captopril 34 – 2 48– 3*a 48 – 3*a 15 – 1 15 – 2 17– 5
SHR
Control 34 – 7 34– 3 33 – 3 21 – 1a 24 – 2a 17– 2
+OPLE 32 – 3 32– 6 33 – 6 18 – 3 20 – 2a 20– 4a
+captopril 40 – 9 48– 2a 39 – 4 20 – 4a 25 – 2a 20– 2a
Data are mean– SEM values.
aP< .05 versus Wistar–Kyoto (WKY) control; *P < .05 versus week 0.
l-NAME, Nx-nitro-l-arginine methyl ester; OPLE, oil palm (E. guineensis) leaf extract; SHR, spontaneously hypertensive.
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unchanged throughout the study. During the course of the
study eight animals died: five from the l-NAME group (one
each at weeks 6, 8, 10, 11, and 12), two from the
l-NAME+OPLE group (at weeks 8 and 9), and one from
the l-NAME + captopril group (at week 7). Three of the
animals from the l-NAME group died between weeks 10
and 12, and postmortem examination showed the deaths
were due to respiratory failure as a result of pulmonary
edema, associated with hypertension-induced cardiac failure
(cor pulmonale); the other two rats died of unknown causes
at weeks 6 and 8. The rats that died from the l-
NAME+ captopril and l-NAME + OPLE groups were also
deaths from unknown causes because they died at night and
the carcasses were already degraded when found the fol-
lowing morning.
Generally, MDA levels increased with age, but the net
increases were lowest (P < .05) in the OPLE-treated hyper-
tensive conditions (l-NAME +OPLE), pointing to the an-















Control 1.22 – 0.06 3.7 – 0.2 333 – 7 0 8 89 – 7 35
+OPLE 1.26 – 0.10 3.9 – 0.3 325 – 1 0 8 79 – 7 32
+captopril 1.02 – 0.04 3.6 – 0.2 291 – 9 0 8 58 – 7a 20a
+l-NAME 1.45 – 0.19 4.5 – 0.7 334 – 14 5 3 27 – 3a 9a
+l-NAME +OPLE 1.48 – 0.11 4.8 – 0.3a 311 – 24 2 6 21 – 2a 8a
+l-NAME + captopril 0.91 – 0.07 3.1 – 0.3b 296 – 6 1 7 16 – 2a 6a
SHR
Control 1.20 – 0.09 4.5 – 0.3 267 – 6a 0 8 29 – 3a 12a
+OPLE 0.93 – 0.10 3.5 – 0.4ac 266 – 5ac 0 8 39 – 3ac 17ac
+captopril 1.16 – 0.16 4.5 – 0.6 258 – 7a 0 8 19 – 2ac 8ac
Data are mean– SEM values.
aP < .05 versus WKY control; bP< .05 versus WKY+ l-NAME; cP < .05 versus SHR control; *P< .05 versus week 0.
FIG. 1. Effect of chronic treatments
with OPLE and captopril on systolic
blood pressure (SBP) of (a) l-NAME-
treated and (b) normal WKY rats. Data
are mean– SEM values.
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tioxidative properties of OPLE. Net MDA increases were
highest (P < .05) in the l-NAME groups (*30% higher than
normal). The OPLE treatment (but not captopril) reduced
this MDA increase (P < .05) by 70% compared with un-
treated l-NAME rats, indicating OPLE’s in vivo anti-
oxidative effects (Table 3). Aging caused activities of
endogenous antioxidant enzymes (erythrocyte SOD, cata-
lase, and GSH-Px) to increase (Table 4). However, under
hypertensive conditions, the reverse was observed for
erythrocyte SOD. The OPLE did not affect the SOD activ-
ities in all groups. Increases in catalase activities were only
significant (P < .05) in the untreated normal and l-
NAME+OPLE rats at week 12. The GSH-Px activity
increases were significant (P < .05) in the untreated hyper-
tensive rats, and both the OPLE and captopril treatments
reversed this trend in l-NAME rats. The temporary changes
in activities of antioxidant enzymes at week 6 (slight re-
duction in GSH-Px activities for most untreated rat groups
and significant [P < .05] catalase increase in l-NAME
groups) may have coincided with sexual maturity.
Chronic l-NAME treatment significantly (P < .05) de-
creased serum NO levels by 80% (week 6), and captopril
significantly (P < .001) maintained the serum NO at normal
levels (Table 5). However, by week 9, the serum NO level in
both the l-NAME and l-NAME+OPLE groups had re-
turned to near normal values, whereas the serum NO level in
l-NAME + captopril rats remained significantly higher than
that of untreated l-NAME rats (P < .01). The OPLE treat-
ment gradually increased serum NO levels of l-NAME rats,
such that by week 12 they were significantly higher than in
the untreated l-NAME rats (P < .05) and similar to those in
normotensive WKY rats. In contrast, the serum NO level
decreased in l-NAME+ captopril rats to baseline levels.
The serum NO level remained unchanged with age in most
groups during the study except in l-NAME rats (P < .05),
which showed a transient reduction at week 6.
Heart
The OPLE treatment significantly reduced MDA (P < .05)
and SOD (P < .05) activities in NO-deficient rats’ hearts
compared with control and l-NAME rats, respectively
(Table 6). No significant differences in catalase and GSH-Px
activities were found among all groups.
Myocardial fibrosis was observed as pink scar patches on
the heart sections, with occasional infiltration with inflam-
matory cells (Fig. 2c). The NO deficiency dramatically in-
creased the fibrosis to 60% compared with control rats
(P < .001). OPLE or captopril co-administration could not
reduce this damage in l-NAME rats (Table 6). The mus-
cle fibers of NO-deficient rats were noticeably thicker,
Table 3. Plasma Malondialdehyde Concentration of Experimental Groups for the Period of Study
Plasma MDA concentration (lmol=L)
WKY group Week 0 Week 6 Week 12
Net MDA increase (lmol=L)
(week 12 – week 0)
Control 5.85 – 0.18 7.06 – 0.09 8.74 – 0.67* 2.89 – 0.34
+OPLE 5.30 – 0.32 5.62 – 0.61 7.50 – 0.51 2.20 – 0.46
+captopril 5.67 – 0.99 6.36 – 0.03 7.83 – 0.49 2.16 – 0.51
+l-NAME 4.66 – 0.86 8.35 – 0.49 8.43 – 0.84* 3.77 – 0.73
+l-NAME+OPLE 6.57 – 0.43 6.59 – 0.36b 7.17 – 0.85 1.13 – 0.52ab
+l-NAME+ captopril 5.44 – 0.28 6.80 – 0.38 8.29 – 0.73* 2.85 – 0.47
Data are mean– SEM values.
aP< .05 versus WKY control; bP< .05 versus WKY+ l-NAME; *P< .05 versus week 0.
MDA, malondialdehyde.
Table 4. Activities of Antioxidant Enzymes in Erythrocytes
of Experimental Groups for the Period of Study
WKY group Week 0 Week 6 Week 9 Week 12
SOD (mU=mL)
Control 13.0 – 0.8 22.8 – 1.1a 16.2 – 01.4 20.1 – 0.7a
+OPLE 14.6 – 1.2 22.7 – 1.0a 18.0 – 0.7 19.5 – 1.0a
+captopril 14.0 – 1.0 21.8 – 0.6a 14.8 – 1.9 18.6 – 0.6a
+l-NAME 13.8 – 0.9 12.0 – 0.9b 08.1 – 0.4ab 10.3 – 1.2b
+l-NAME+
OPLE
12.7 – 1.4 09.9 – 0.7b 06.5 – 0.9ab 10.7 – 0.8b
+l-NAME+
captopril
13.3 – 1.0 12.6 – 1.1b 07.2 – 0.8ab 10.8 – 0.8b
Catalase (mU=mL)
Control 11.4 – 0.9 13.6 – 1.1 12.8 – 0.4 13.9 – 0.5a
+OPLE 13.2 – 0.7 13.6 – 1.3 15.6 – 0.7 17.6 – 0.8
+captopril 13.5 – 0.6 13.4 – 0.3 14.0 – 0.5 13.1 – 0.8
+l-NAME 11.8 – 0.7 15.0 – 0.7a 11.5 – 0.6 13.8 – 0.5
+l-NAME+
OPLE
12.4 – 0.4 12.9 – 0.6 12.6 – 0.7 15.4 – 0.9a
+l-NAME+
captopril
12.9 – 0.5 12.5 – 0.5 13.1 – 0.6 14.3 – 0.3
GSH-Px (U=mL)
Control 19.8 – 3.8 18.8 – 2.5 20.0 – 5.8 24.3 – 4.2
+OPLE 20.7 – 3.2 25.2 – 3.8 22.6 – 4.9 27.0 – 3.2
+captopril 16.5 – 0. 9 21.1 – 5.1 14.1 – 1.8 26.2 – 4.4
+l-NAME 22.6 – 1.8 10.0 – 1.3a 15.9 – 1.8 31.2 – 3.2a
+l-NAME+
OPLE
21.4 – 5.7 14.0 – 4.0 16.5 – 1.7 18.9 – 1.9
+l-NAME+
captopril
22.1 – 3.1 14.2 – 2.0 16.6 – 2.7 17.2 – 0.9
Data are mean– SEM values.
aP< .05 versus week 0 (for the respective group); bP< .05 versus
normotensive WKY control.
GSH-Px, glutathione peroxidase; SOD, superoxide dismutase.
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indicating hypertrophy (P < .001). Unlike the l-NAME+
OPLE group, the l-NAME + captopril group demonstrated
near-normal myocardium, with no increase in thickness.
Changes in coronary small arteries
The coronary artery walls were noticeably thickened after
12 weeks of NO deficiency (Table 6) with significant
changes in the wall-to-lumen ratio compared with control
rats (P < .005). There were decreases in artery wall thickness
with concomitant administration of OPLE or captopril re-
sulting in decreased wall-to-lumen ratios to normal values
(Table 6). The aorta wall thickness and coronary artery wall-
to-lumen ratio of all normotensive WKY rats were similar,
and neither OPLE nor captopril affected them.
DISCUSSION
BP effects
Phenolic compounds purportedly enhance vascular NO
activities, either by inducing NO production through NO
synthase expression or by their direct antioxidant effect,
thereby protecting NO against oxidative destruction.23
l-NAME inhibits NO synthesis, impairing endothelial-
dependent vasodilation, and additionally induces hyperten-
sion via excess O2
– formation, from the vascular smooth
muscle layer,23 and contributes to the reduced serum NO in
these rats (Table 5), whereas O2
– accelerated the degrada-
tion of NO to peroxynitrite.24 The l-NAME-induced hy-
pertension would cause significant angiotensin converting
enzyme activity elevation in the heart and aorta after 4
weeks.25 Overproduction of local angiotensin II would thus
lead to increased vascular O2
– formation through the ex-
pression of NADPH-dependent oxidase in aortic smooth
muscle cells.26 Captopril inhibits angiotensin converting
enzyme, increases the NO=O2
– ratio, reduces NADPH oxi-
dase activity resulting in normalized BP,27 and normalizes
serum NO (Table 5). The NADPH oxidase and the endo-
thelial NO synthase are the major sources of superoxides in
the endothelial cells.28 The catechin-rich OPLE normalizes
BP in NO-deficient rats, most likely by quenching the su-
peroxides, resulting in BP effects similar to that of captopril
although probably via different mechanisms. More impor-
tant is that OPLE did not alter the BP of normotensive rats.
Cardiovascular tissue effects
The cardiosomatic index is a gross indicator of left
ventricle hypertrophy. The cardiosomatic indices for the
l-NAME and l-NAME +OPLE groups were not signifi-
cantly different from each other, but that of l-NAME+
OPLE was higher than that of normotensive rats. However,
both groups were beginning to develop left ventricle hy-
pertrophy, associated with an increased protein synthesis in
cardiac myocytes and increased myocardial fibrosis. In con-
trast, l-NAME+ captopril rats displayed reduced cardioso-
matic index and myocardial fiber thickness, although the
degrees of fibrosis were similar to those of the l-NAME group.
The catechin-rich OPLE was able to inhibit the l-NAME-
induced NO-deficiency hypertension, but not the associated
Table 5. Serum Nitric Oxide Values of Experimental Groups for the Period of Study
Nitric oxide (ppm)
WKY group Week 0 Week 6 Week 9 Week 12
Control 0.414– 0.024 0.548– 0.009 0.417 – 0.053 0.384– 0.038
+OPLE 0.347– 0.014 0.409– 0.109 0.468 – 0.096 0.362– 0.002
+captopril 0.381– 0.023 0.573– 0.024 0.455 – 0.060 0.525– 0.071
+l-NAME 0.339– 0.034 0.104– 0.056ab 0.276 – 0.061 0.210– 0.074
+l-NAME +OPLE 0.319– 0.044 0.197– 0.053b 0.283 – 0.084 0.531– 0.086c
+l-NAME + captopril 0.402– 0.008 0.585– 0.082c 0.742 – 0.123bc 0.44 – 0.072
Data are mean– SEM values.
aP < .05 versus week 0 (for the respective group); bP < .05 versus normotensive WKY control within the same week; cP< .05 versus l-NAME.
Table 6. Superoxide Dismutase, Catalase, and Glutathione Peroxidase Activities










Control 23.49– 2.17 3.91 – 0.07 4.39 – 0.56 3.35 – 0.71
+OPLE 18.77– 1.99 3.69 – 0.11 6.08 – 1.02 4.16 – 0.71
+captopril 17.54– 0.41 3.91 – 0.004 5.42 – 1.02 5.20 – 1.14
+l-NAME 18.73– 3.17 4.54 – 0.80 5.02 – 0.99 5.33 – 0.48
+l-NAME +OPLE 13.01– 1.20a 3.25 – 0.21b 4.11 – 0.53 4.69 – 0.44
+l-NAME + captopril 18.31– 2.05 3.64 – 0.36 4.31 – 0.78 4.84 – 0.36
Data are mean– SEM values (n = 8).
aP < .05 versus WKY control; bP< .05 versus WKY+ l-NAME.
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cardiac hypertrophy. Similarly, red wine polyphenols re-
portedly reduced BP, increased NO synthase activity, and
prevented myocardial fibrosis in l-NAME rats without af-
fecting left ventricle hypertrophy.28 Cardiac hypertrophy in
l-NAME-treated animals is remedial to chronic hyperten-
sion and is associated with plasma renin activity increases.28
Plasma renin is higher in animals treated with lower doses
than with greater doses of l-NAME.28 This may explain the
cardiac hypertrophy in the l-NAME +OPLE group. In
contrast, green tea extract, another rich source of catechin,
successfully prevented BP increases and attenuated cardiac
hypertrophy in an angiotensin II rat model of hypertension,
probably because of the high dose (1 g=kg=day) of green tea
extract used.29
Hypertension causes coronary artery narrowing, due to
arterial structural changes to withstand the increasing pres-
sure on the arterial wall. The increased wall-to-lumen ratio
indicated remodeling of the small arterial wall. With OPLE
treatment, vascular remodeling was reduced as the wall-to-
lumen ratio was not as extensive as in the untreated
l-NAME rats. The attenuation in BP increases by OPLE
apparently minimizes artery structural changes. In OPLE-
treated normal rats, the normal appearance of myocardium
and unchanged antioxidant status confirmed that OPLE was
not cardiotoxic. The catechins have enzyme and cell sig-
naling modulating properties,30 thus providing some pro-
tection and reducing certain metabolic dysfunctions.
Antioxidant effects
The l-NAME treatment increased MDA (a lipid perox-
idation product) levels (by 80%) and reduced erythrocyte
SOD and GSH-Px activities in week 6, compared with
normal rats. This increased oxidation inactivated GSH-Px,
resulting in an enhanced H2O2 level, which in turn in-
activated SOD.31 By week 12 the enzymes had been up-
regulated, in response to the oxidative stress. Catalase
activities slightly increased with age but remained stable
when compared among groups at any week. The catechin-
rich OPLE gradually improved serum NO levels in l-NAME
rats and significantly by 12 weeks. The OPLE significantly
reduced plasma MDA content in l-NAME rats, confirming
its antioxidative abilities to reduce oxidative stress.
Other investigators showed that (–)-epicatechin can im-
prove BP in hypertensive patients, decrease infarct size in
myocardial ischemia–reperfusion injury animal models, and
reduce myocardial infarction size and left ventricular scar
area strains.32 Recent reports indicate that (–)-epicatechin
exerted cardioprotective actions, partly via endothelial NO
synthase–mediated NO production in endothelial cells. The
FIG. 2. Effect of chronic treatments with OPLE and
captopril in normal and nitric oxide–deficient WKY rats
on (a) coronary arteriole wall-to-lumen ratio, (b) myo-
cardial fiber thickness, and (c) percentage of myocardial
fibrosis. *P< .05 versus control, +P< .05 versus l-
NAME.
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(–)-epicatechin apparently only partially stimulated NO
production in cells, involving a cell surface acceptor–
effector. (–)-Epicatechin treatment activates endothelial NO
synthase via Ser633and Ser1177 phosphorylation, Thr495 de-
phosphorylation, and the phosphatidylinositol 3-kinase
pathway and at least partially mediated via the Ca2+=cal-
modulin kinase II pathway.33 Epidemiological studies con-
sistently associate high flavonoid intake with a reduced risk
of cardiovascular diseases, linked to nonspecific antioxidant
and anti-inflammatory properties. An increasing body of
evidence suggests that flavonoids specifically target mo-
lecular structures including cardiovascular ion channels,
important in vascular tone regulation and cardiac electric
activity, thus inducing antihypertensive and cardioprotec-
tive effects.34
Hypertension and cardiovascular disease are associated
with hyperglycemia and dyslipidemia, low-grade inflam-
mation, and serum NO-linked insulin resistance. Other an-
imal models have been used to study these effects.35 The
protective mechanisms of dietary flavonoids and green tea
catechins against cardiovascular disease risk include
through (1) antioxidant actions, (2) central nervous system
effects, (3) intestinal transport alterations, (4) fatty acid
sequestration and processing, (5) peroxisome proliferator-
activated receptor activation, (6) increased insulin sensi-
tivity,36 (7) maintaining endothelial functions, vascular
homeostasis, and decreased atherogenesis,37 (8) vascular
NO production,38 and (9) inflammatory and endothelial
apoptosis modulation.39 EGCG was reported to help prevent
cardiac hypertrophy and hypertension by suppressing (1)
angiotensin II and pressure overload, (2) reactive oxygen
species generation and NADPH oxidase overexpressions,
(3) nuclear factor-jB and activator protein-1 activation, (4)
reactive oxygen species–dependent p38 and c-Jun N-
terminal kinase signaling pathways, (5) epidermal growth
factor receptor transactivation, (6) extracellular signal-
regulated kinases=phosphatidylinositol 3-kinase=Akt=mTOR=
p70 (S6K), and (7) reactivation of atrial natriuretic peptide
and brain natriuretic peptide and is involved in inhibition of
various intracellular signaling transductional pathways.40
Epicatechin and its procyanidin oligomers inhibit angio-
tensin converting enzyme activity, with the tetramer being
the most active inhibitor.41 EGCG but not EGC apparently
inhibited the angiotensin II-stimulated (1) vascular smooth
muscle cell hypertrophy and (2) c-Jun N-terminal kinase
signaling pathway at both the transcriptional and post-
translational levels, but did not change extracellular signal-
regulated kinase and p38 mitogen-activated protein
kinase.42 Future investigation to measure inducible NOS
and other enzyme or signaling activities may help confirm
the mechanisms of OPLE catechins.
CONCLUSIONS
This is the first report on the in vivo antihypertensive
properties of catechins extracted from an alternative source,
namely, oil palm leaf, for use as a medicinal food for hy-
pertension and other cardiovascular ailments. The OPLE
catechins alleviated NO-deficiency hypertension by (1)
normalizing serum NO levels, (2) producing antioxidant
effects, and (3) enhancing endothelial NO bioactivity pos-
sibly via O2
– scavenging ability in hypertensive rats. The
OPLE catechins showed some cardioprotective effects by
reducing coronary arteriole wall thickening induced by NO
deficiency and showed no chronic toxicity to the cardio-
vascular system.
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